文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Vutrisiran对转甲状腺素蛋白淀粉样变心肌病心脏生物标志物的影响:HELIOS-B研究

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

HELIOS-B双盲安慰剂对照研究纳入655例ATTR-CM患者,评估基线NT-proBNP和肌钙蛋白I的预后价值及vutrisiran对生物标志物的影响。基线两者均独立关联复合终点和全因死亡(P<0.0001)。第30个月vutrisiran组NT-proBNP和肌钙蛋白I几何均值倍数变化比均为0.68(P<0.0001)。

要点

  • 基线NT-proBNP和肌钙蛋白I独立预测ATTR-CM复合终点和全因死亡。
  • 第6个月NT-proBNP升高关联更高风险,肌钙蛋白I降低关联复合终点风险降低。
  • vutrisiran使NT-proBNP和肌钙蛋白I水平维持稳定或降低,几何均值倍数变化比均为0.68。

核心结论

  • 生物标志物与不良结局的关联模式支持ATTR-CM早期治疗的重要性及风险降低潜力。
  • Vutrisiran维持或降低NT-proBNP和肌钙蛋白I水平,与降低心血管事件和全因死亡风险的获益一致。

研究设计与样本

  • HELIOS-B为双盲、安慰剂对照研究,655例ATTR-CM患者按1:1随机接受vutrisiran或安慰剂,最长36个月。
  • 主要终点为全因死亡和复发性心血管事件的复合终点,至42个月的全因死亡为次要终点,NT-proBNP和肌钙蛋白I为预设探索性终点。

主要发现

  • 基线NT-proBNP和肌钙蛋白I水平均独立关联复合终点和全因死亡风险(两者及两终点P<0.0001)。
  • 第6个月NT-proBNP较基线升高关联复合终点和全因死亡更高风险,肌钙蛋白I降低关联复合终点风险降低。
  • 第30个月安慰剂组NT-proBNP和肌钙蛋白I中位变化分别为753 pg/mL(Q1-Q3:-8至2,573 pg/mL)和9.7 pg/mL(Q1-Q3:-6.3至41.2 pg/mL)。
  • 第30个月vutrisiran组NT-proBNP和肌钙蛋白I中位变化分别为118 pg/mL(Q1-Q3:-419至911 pg/mL)和-5.8 pg/mL(Q1-Q3:-25.0至10.0 pg/mL)。
  • 第30个月vutrisiran/安慰剂几何均值倍数变化比:NT-proBNP 0.68(95%CI:0.61-0.76),肌钙蛋白I 0.68(95%CI:0.62-0.75),P均<0.0001。

临床怎么用

  • 基线及随访NT-proBNP和肌钙蛋白I可用于ATTR-CM风险分层。
  • vutrisiran治疗可稳定或降低NT-proBNP和肌钙蛋白I,支持其心脏获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Before the development of disease-modifying therapies for transthyretin amyloidosis cardiomyopathy (ATTR-CM), N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) and troponin I/T were recognized as independent prognostic biomarkers of mortality. This study evaluated the prognostic value of these biomarkers in a contemporary patient population and the impact of vutrisiran, an RNA interference therapeutic that rapidly knocks down circulating transthyretin, on biomarker levels. OBJECTIVES: This study sought to evaluate the association between risk of cardiovascular events and all-cause mortality with baseline NT-proBNP and troponin I levels and changes from baseline at month 6 in patients from HELIOS-B and explore how vutrisiran impacts biomarkers over time. METHODS: In HELIOS-B, a double-blind, placebo-controlled study, 655 patients with ATTR-CM were randomized 1:1 to receive vutrisiran or placebo for up to 36 months. The primary endpoint was a composite outcome of all-cause mortality and recurrent cardiovascular events. All-cause mortality through 42 months was a secondary endpoint. NT-proBNP and troponin I were assessed as prespecified exploratory endpoints. RESULTS: Baseline NT-proBNP and troponin I levels were independently associated with risks of the composite outcome and all-cause mortality (P < 0.0001 for both biomarkers and endpoints). At month 6, increases in NT-proBNP from baseline were associated with higher risk of the composite outcome and all-cause mortality, and decreases in troponin I were associated with a lower risk of the composite outcome. At month 30, the median changes from baseline of NT-proBNP and troponin I were 753 pg/mL (Q1-Q3: -8 to 2,573 pg/mL) and 9.7 pg/mL (Q1-Q3: -6.3 to 41.2 pg/mL) in the placebo arm and 118 pg/mL (Q1-Q3: -419 to 911 pg/mL) and -5.8 pg/mL (Q1-Q3: -25.0 to 10.0 pg/mL) in the vutrisiran arm. The geometric mean fold-change ratios (vutrisiran/placebo) were 0.68 (95% CI: 0.61-0.76) for NT-proBNP and 0.68 (95% CI: 0.62-0.75) for troponin I (P < 0.0001 for both). CONCLUSIONS: Patterns of associations between biomarkers and adverse outcomes support the importance of early treatment initiation and the potential for risk reduction in patients with ATTR-CM. Vutrisiran maintained stable or reduced levels of both biomarkers consistent with the benefit of treatment in reducing the risk of cardiovascular events and all-cause mortality. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Maurer MS, Berk JL, Damy T, et al. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025. PMID: 40769675. doi:10.1016/j.jacc.2025.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。